BIOMAT Database Logo BIOMAT Database Logo

Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. 1998

S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Department of Medicinal Chemistry, Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen, Denmark.

A large number of substituted chalcones have been synthesized and tested for antileishmanial and lymphocyte-suppressing activities. A subset of the chalcones was designed by using statistical methods. 3D-QSAR analyses using 67 (antileishmanial activity) and 63 (lymphocyte-suppressing activity) of the compounds for the training sets and 9 compounds as an external validation set were performed by using the GRID/GOLPE methodology. The Smart Region Definition procedure with subsequent region selection as implemented in GOLPE reduced the number of variables to approximately 1300 yielding 3D-QSAR models of high quality (lymphocyte-suppressing model, R2 = 0. 90, Q2 = 0.80; antileishmanial model, R2 = 0.73, Q2 = 0.63). The coefficient plots indicate that steric interactions between the chalcones and the target are of major importance for the potencies of the compounds. A comparison of the coefficient plots for the antileishmanial effect and the lymphocyte-suppressing activity discloses significant differences which should make it possible to design chalcones having a high antileishmanial activity without suppressing the proliferation of lymphocytes.

UI MeSH Term Description Entries
D007893 Leishmania donovani A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). The sandfly genera Phlebotomus and Lutzomyia are the vectors. Leishmania (Leishmania) donovani,Leishmania leishmania donovani,Leishmania donovanus,Leishmania leishmania donovanus,donovani, Leishmania leishmania,donovanus, Leishmania,donovanus, Leishmania leishmania,leishmania donovanus, Leishmania
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002599 Chalcone An aromatic KETONE that forms the core molecule of CHALCONES. Benzalacetophenone,Benzylideneacetophenone,1,3-Diphenyl-2-Propen-1-One,Chalkone,1,3 Diphenyl 2 Propen 1 One
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014344 Trypanocidal Agents Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. Trypanocidal Drugs,Trypanocides,Trypanosomicidal Agents,Trypanosomicides,Agents, Trypanocidal,Agents, Trypanosomicidal,Drugs, Trypanocidal

Related Publications

S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Design, synthesis, antifungal activity, and structure-activity relationship studies of chalcones and hybrid dihydrochromane-chalcones.
August 2020, Molecular diversity,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Design, Synthesis, Structure-Activity Relationship, and Three-Dimensional Quantitative Structure-Activity Relationship of Fusarium Acid Derivatives and Analogues as Potential Fungicides.
November 2023, Journal of agricultural and food chemistry,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Antileishmanial pyrazolopyridine derivatives: synthesis and structure-activity relationship analysis.
October 2004, Journal of medicinal chemistry,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Design and Synthesis of New Anthranyl Phenylhydrazides: Antileishmanial Activity and Structure-Activity Relationship.
August 2023, Pharmaceuticals (Basel, Switzerland),
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Structure-activity relationships of antileishmanial and antimalarial chalcones.
July 2003, Bioorganic & medicinal chemistry,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
March 2007, Drug metabolism and disposition: the biological fate of chemicals,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Molecular design of anticancer drug leads based on three-dimensional quantitative structure-activity relationship.
August 2011, Journal of chemical information and modeling,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Synthesis of fluorescent chalcones, photophysical properties, quantitative structure-activity relationship and their biological application.
April 2023, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.
October 1999, The Journal of pharmacology and experimental therapeutics,
S F Nielsen, and S B Christensen, and G Cruciani, and A Kharazmi, and T Liljefors
Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
April 2012, Journal of chemical information and modeling,
Copied contents to your clipboard!